Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>On the latest WTR Healthcare Happenings podcast, we were joined by Luke McFarlane, CEO and Co-Founder of Natural MedTech (NMT), an Australia-based privately held pharmaceutical API manufacturer and supplier that specializes in hard-to-synthesize psychedelic molecules, including psilocybin and MDMA for pharmaceutical and clinical-trial use to unlock neurologic potential. </li><li>We discussed NMT’s proprietary biosynthesis platform, manufacturing strategy, the role of AI in drug development, and the company’s ambitions across the medicinal psychedelic supply chain, including opportunities beyond API manufacturing</li><li>Meet the CEO. Luke McFarlane came to psychedelic manufacturing from financial markets rather than pharma. </li></ul>

On the latest WTR Healthcare Happenings podcast, we were joined by Luke McFarlane, CEO and Co-Founder of Natural MedTech (NMT), an Australia-based privately held pharmaceutical API manufacturer and supplier that specializes in hard-to-synthesize psychedelic molecules, including psilocybin and MDMA for pharmaceutical and clinical-trial use to unlock neurologic potential. We discussed NMT’s proprietary biosynthesis platform, manufacturing strategy, the role of AI in drug development, and the company’s ambitions across the medicinal psychedelic supply chain, including opportunities beyond API manufacturingMeet the CEO. Luke McFarlane came to psychedelic manufacturing from financial markets rather than pharma. 

WTR Healthcare Happenings Podcast Recap : Natural MedTech (NMT)